Comprehensive analysis supports SERMs for cutting breast cancer

April 30, 2013
Comprehensive analysis supports SERMs for cutting breast cancer
Treatment with selective estrogen receptor modulators is associated with a significant reduction in the incidence of breast cancer, especially for the first five years after treatment, according to research described as the first comprehensive analysis, published online April 30 in The Lancet.

(HealthDay)—Treatment with selective estrogen receptor modulators (SERMs) is associated with a significant reduction in the incidence of breast cancer, especially for the first five years after treatment, according to research described as the first comprehensive analysis, published online April 30 in The Lancet.

Jack Cuzick, Ph.D., from the Queen Mary University of London, and colleagues conducted a meta-analysis using data from nine to examine the effectiveness of SERMs on the incidence of breast cancer. Data were analyzed for 83,399 women who were followed for a mean of 65 months for a total of 306,617 women-years of follow-up.

The researchers found that there was a significant, 38 percent reduction overall in the incidence of breast cancer, and that within the first 10 years of follow-up, 42 women needed to be treated to prevent one breast cancer event. In the first five years of follow-up, the reduction was larger than in years five to 10 (hazard ratio, 0.58), but there was no heterogeneity between time periods. With all SERMS, the likelihood of thromboembolic events was significantly increased (odds ratio [OR], 1.73). There was a significant reduction in vertebral fractures (OR, 0.66), while the reduction for non- was smaller, but still significant (OR, 0.93).

"For all SERMs, incidence of invasive estrogen-positive was reduced both during treatment and for at least five years after completion," the authors write. "Similar to other , careful consideration of risks and benefits is needed to identify women who are most likely to benefit from these drugs."

One author disclosed to AstraZeneca; two authors disclosed ties to Eli Lilly.

Explore further: Estrogen-only HRT continues to protect women against breast cancer long after they have stopped

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Estrogen-only HRT continues to protect women against breast cancer long after they have stopped

March 6, 2012
Women who use the oestrogen-only form of hormone replacement therapy (HRT) appear less likely to develop breast cancer in the longer term, according to new research published Online First in The Lancet Oncology. A follow-up ...

SABCS: Extending tamoxifen to 10 years beneficial in breast CA

December 5, 2012
(HealthDay)—For women with estrogen receptor (ER)-positive early breast cancer, continuing tamoxifen to 10 years correlates with reduced risk of recurrence and lower breast cancer-specific and overall mortality, according ...

CDC: breast cancer mortality higher in black women

November 15, 2012
(HealthDay)—With earlier detection and better treatment, the mortality rate from breast cancer has fallen over the last two decades; black women, however, still die from the disease at a disproportionately higher rate than ...

Recommended for you

How cancer metastasis happens: Researchers reveal a key mechanism

January 18, 2018
Cancer metastasis, the migration of cells from a primary tumor to form distant tumors in the body, can be triggered by a chronic leakage of DNA within tumor cells, according to a team led by Weill Cornell Medicine and Memorial ...

Modular gene enhancer promotes leukemia and regulates effectiveness of chemotherapy

January 18, 2018
Every day, billions of new blood cells are generated in the bone marrow. The gene Myc is known to play an important role in this process, and is also known to play a role in cancer. Scientists from the German Cancer Research ...

These foods may up your odds for colon cancer

January 18, 2018
(HealthDay)—Chowing down on red meat, white bread and sugar-laden drinks might increase your long-term risk of colon cancer, a new study suggests.

The pill lowers ovarian cancer risk, even for smokers

January 18, 2018
(HealthDay)—It's known that use of the birth control pill is tied to lower odds for ovarian cancer, but new research shows the benefit extends to smokers or women who are obese.

Researchers develop swallowable test to detect pre-cancerous Barrett's esophagus

January 17, 2018
Investigators at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center have developed a simple, swallowable test for early detection of Barrett's esophagus that offers promise ...

Scientists zoom in to watch DNA code being read

January 17, 2018
Scientists have unveiled incredible images of how the DNA code is read and interpreted—revealing new detail about one of the fundamental processes of life.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.